Silent information regulator, Sirtuin 1, and age-related diseases

Geriatrics and Gerontology International

Volumn 9, Issue 1, 2009, Pages 7-15

  Zeng, Li ^a   Chen, Rui ^a,b   Liang, Fengxia ^a,c   Tsuchiya, Hiroshi ^a   Murai, Hiroshi ^a   Nakahashi, Takeshi ^a   Iwai, Kunimitsu ^a   Takahashi, Takashi ^a,d   Kanda, Tsugiyasu ^a   Morimoto, Shigeto ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Age related disease; Forkhead box class O (FOXO); Nuclear factor B (NF B); p53; Sirtuin1 (SIRT1)

Indexed keywords

ABC TRANSPORTER A1; ADIPONECTIN; ANDROGEN RECEPTOR; CAMBINOL; CCAAT ENHANCER BINDING PROTEIN; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; KU ANTIGEN; LIVER X RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUCLEAR RECEPTOR COREPRESSOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 6; PROTEIN KINASE B; PROTEIN P53; RESVERATROL; SIRTUIN 1; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; UNINDEXED DRUG; VASCULOTROPIN C;

AGING; ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; B CELL LYMPHOMA; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLON CARCINOMA; DEGENERATIVE DISEASE; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; HEART FAILURE; HEART PROTECTION; HUMAN; LYMPH NODE METASTASIS; METABOLIC DISORDER; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR VASCULARIZATION;

AGE FACTORS; AGED; GERIATRICS; HEART DISEASES; HUMANS; METABOLIC DISEASES; NEOPLASMS; SIRTUINS;

EID: 61549114593     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2008.00504.x     Document Type: Review

References (75)

1. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005; 120: 473-482.
2. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800.
3. Jeong J, Juhn K, Lee H et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39: 8-13.
4. Cohen HY, Lavu S, Bitterman KJ et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627-638.
5. Narala SR, Allsopp RC, Wells TB et al. SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell 2008; 19: 1210-1219.
6. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007; 28: 277-290.
7. Luo J, Nikolaev AY, Imai S et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148.
8. Brunet A, Sweeney LB, Sturgill JF etal. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-2015.
9. Ghosh HS, Spencer JV, Ng B et al. Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J 2007; 408: 105-111.
10. Higashitsuji H, Higashitsuji H, Liu Y et al. The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. Biochem Biophys Res Commun 2007; 363: 879-884.
11. Li J, Wang E, Rinaldo F, Datta K. Upregulation of VEGF-C by androgen depletion: The involvement of IGF-IR-FOXO pathway. Oncogene 2005; 24: 5510-5520.
12. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005; 24: 1021-1032.
13. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118.
14. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007; 282: 34356-34364.
15. Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 2008; 7: 78-88.
16. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106.
17. Wallerath T, Deckert G, Ternes T et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002; 106: 1652-1658.
18. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP. Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 2005; 288: H486-H496.
19. + depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 2005; 280: 43121-43130.
20. Saunders LR, Verdin E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-5504.
21. Huffman DM, Grizzle WE, Bamman MM et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 2007; 67: 6612-6618.
22. Stünkel W, Peh BK, Tan YC et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2: 1360-1368.
23. Boulton SJ, Jackson SP. Saccharomyces cerevisiae Ku70 potentiates illegitimate DNA double-strand break repair and serves as a barrier to error-prone DNA repair pathways. EMBO J 1996; 15: 5093-5103.
24. Huo LF, Tang JW, Huang JJ et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 2006; 3: 1-11.
25. Jang M, Cai L, Udeani GO et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
26. Bickenbach KA, Veerapong J, Shao MY et al. Resveratrol is an effective inducer of C. ArG-driven TNF-alpha gene therapy. Cancer Gene Ther 2008; 15: 133-139.
27. Hollstein M, Rice K, Greenblatt MS et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-3555.
28. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 2005; 7: 752-760.
29. Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 2004; 117: 421-426.
30. Luedde T, Beraza N, Kotsikoris V et al. Deletion of NEMO/IK. Kgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132.
31. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977-990.
32. Nahle Z, Polakoff J, Davuluri RV et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nature Cell Biol 2002; 4: 859-864.
33. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 2001; 15: 1833-1844.
34. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365: 349-352.
35. Wang C, Chen L, Hou X et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006; 8: 1025-1031.
36. Potente M, Ghaeni L, Baldessari D et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007; 21: 2644-2658.
37. Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-4377.
38. Lagouge M, Argmann C, Gerhart-Hines Z et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122.
39. Milne JC, Lambert PD, Schenk S et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-716.
40. Yoon JC, Puigserver P, Chen G et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1α. Nature 2001; 413: 131-138.
41. Puigserver P, Rhee J, Donovan J et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1α interaction. Nature 2003; 423: 550-555.
42. Lin J, Wu PH, Tarr PT et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1α null mice. Cell 2004; 119: 121-135.
43. Picard F, Kurtev M, Chung N et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776.
44. Nakae J, Biggs WH 3rd, Kitamura T et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002; 32: 245-253.
45. Nakae J, Kitamura T, Kitamura Y, Biggs WH 3rd, Arden KC, Accili D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell 2003; 4: 119-129.
46. Kahn CR, Vicent D, Doria A. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 1996; 47: 509-531.
47. Muzumdar R, Ma X, Atzmon G, Vuguin P, Yang X, Barzilai N. Decrease in glucose-stimulated insulin secretion with aging is independent of insulin action. Diabetes 2004; 53: 441-446.
48. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-1792.
49. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006; 281: 39915-39924.
50. Qiang L, Wang H, Farmer SR. Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 2007; 27: 4698-4707.
51. Kuningas M, Putters M, Westendorp RG, Slagboom PE, van Heemst D. SIRT1 gene, age-related diseases, and mortality: The Leiden 85-plus study. J Gerontol A Biol Sci Med Sci 2007; 62: 960-965.
52. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005; 4: 193-205.
53. Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-1310.
54. Mattagajasingh I, Kim CS, Naqvi A et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104: 14855-14860.
55. Miatello R, Vázquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18: 864-870.
56. Nadal-Ginard B, Kajstura J, Anversa P, Leri A. A matter of life and death: Cardiac myocyte apoptosis and regeneration. J Clin Invest 2003; 111: 1457-1459.
57. Cheng HL, Mostoslavsky R, Saito S et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003; 100: 10794-10799.
58. Sakamoto J, Miura T, Shimamoto K, Horio Y. Predominant expression of Sir2alpha, an NAD-dependent histone deacetylase, in the embryonic mouse heart and brain. FEBS Lett 2004; 556: 281-286.
59. Crow MT. Sir-viving cardiac stress: Cardioprotection mediated by a longevity gene. Circ Res 2004; 95: 953-956.
60. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004; 95: 971-980.
61. Alcendor RR, Gao S, Zhai P et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 2007; 100: 1512-1521.
62. Kim D, Nguyen MD, Dobbin MM et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-3179.
63. Duan W, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res 1999; 57: 195-206.
64. Vaziri H, Dessain SK, Ng Eaton E et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-159.
65. Motta MC, Divecha N, Lemieux M et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-563.
66. Chen J, Zhou Y, Mueller-Steiner S et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
67. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-1013.
68. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
69. Detmer SA, Chan DC. Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 2007; 8: 870-879.
70. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109.
71. Gerhart-Hines Z, Rodgers JT, Bare O et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/ PGC-1alpha. EMBO J 2007; 26: 1913-1923.
72. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008; 118: 421-428.
73. Bäckesjö CM, Li Y, Lindgren U, Haldosén LA. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res 2006; 21: 993-1002.
74. Kodama Y, Seyama K, Yoshimi K et al. Survey of implementation of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in nine Asian countries. Geriatr Gerontol Int 2007; 7: 174-183.
75. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 861-870.